Long Covid patients suffer from chronic symptoms such as fatigue or shortness of breath. As researchers have discovered, this is to some extent due to a part of our immune system called the complement ...
Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results